GLP-1 Medications Compared: Semaglutide vs. Tirzepatide vs. Liraglutide

Three GLP-1 receptor agonists dominate the weight loss medication conversation right now: semaglutide (Wegovy/Ozempic), tirzepatide (Mounjaro/Zepbound), and liraglutide (Saxenda). They all work through related mechanisms, but they are not interchangeable. The differences in effectiveness, side effects, dosing, and cost matter — and the best choice for you depends on factors that go beyond which one produced the best average weight loss in clinical trials.

Here is what the evidence actually says about each one.

How They Work: Same Family, Different Mechanisms

All three medications belong to the GLP-1 receptor agonist class, meaning they mimic the GLP-1 hormone your body produces naturally after eating. GLP-1 slows stomach emptying, reduces appetite, and helps regulate blood sugar.

But there is an important distinction:

Semaglutide (Wegovy, Ozempic) is a pure GLP-1 receptor agonist. It targets the GLP-1 receptor only.

Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist. It targets both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP is another incretin hormone involved in insulin secretion and energy metabolism. This dual action appears to provide additional weight loss benefit beyond GLP-1 alone.

Liraglutide (Saxenda, Victoza) is also a pure GLP-1 receptor agonist, but it has a shorter half-life than semaglutide, requiring daily injections rather than weekly.

Head-to-Head Effectiveness

Let's look at what the major clinical trials showed:

| Medication | Average Weight Loss | Trial | Duration |

|---|---|---|---|

| Tirzepatide 15 mg | ~22.5% of body weight | SURMOUNT-1 | 72 weeks |

| Semaglutide 2.4 mg | ~15-17% of body weight | STEP 1 | 68 weeks |

| Liraglutide 3.0 mg | ~7-8% of body weight | SCALE | 56 weeks |

These are averages, and individual results vary significantly. Some patients on semaglutide lose 20% or more, while some on tirzepatide may lose closer to 15%. But the trend is clear: tirzepatide produces the most weight loss on average, followed by semaglutide, with liraglutide third.

The SURMOUNT-3 and SURMOUNT-4 trials further confirmed tirzepatide's weight loss efficacy, with some participants achieving 25% or greater total body weight loss — numbers that begin approaching what is seen with bariatric surgery.

An important caveat: these trials used specific patient populations and controlled conditions. Real-world results depend on medication adherence, lifestyle factors, starting weight, metabolic health, and individual biology. The "best" medication on paper may not be the best medication for a specific patient.

Dosing and Administration

| | Semaglutide (Wegovy) | Tirzepatide (Zepbound) | Liraglutide (Saxenda) |

|---|---|---|---|

| Route | Subcutaneous injection | Subcutaneous injection | Subcutaneous injection |

| Frequency | Once weekly | Once weekly | Once daily |

| Starting dose | 0.25 mg/week | 2.5 mg/week | 0.6 mg/day |

| Target dose | 2.4 mg/week | Up to 15 mg/week | 3.0 mg/day |

| Titration period | 16-20 weeks | 20+ weeks | 4-5 weeks |

| Oral option | Yes (approved Feb 2026) | Not yet | No |

The daily dosing requirement of liraglutide is a practical disadvantage for most patients. Weekly injections with semaglutide or tirzepatide are simpler to maintain over the long term. Semaglutide now also has an oral option for patients who prefer pills over injections.

Side Effects: How They Compare

The GI side effects are similar across all three because they share the GLP-1 mechanism:

• Nausea (most common, especially during dose increases)
• Vomiting
• Diarrhea
• Constipation
• Abdominal pain

Tirzepatide tends to have a slightly higher rate of GI side effects at the highest doses, which makes sense given it acts on two receptors instead of one. However, the slow titration schedule helps most patients adapt.

Semaglutide has the most long-term safety data among the three for weight management, given the size and scope of the STEP trial program.

Liraglutide has the longest overall track record — it was the first GLP-1 approved for weight loss (2014). Some patients tolerate it better than the more potent options, though the daily injection is a tradeoff.

All three carry warnings about potential thyroid C-cell tumors (based on animal studies), pancreatitis risk, and gallbladder-related events. These risks are rare but important to discuss with your physician.

Beyond Weight Loss: Other Health Benefits

GLP-1 medications are not just weight loss drugs. They have documented benefits for:

Cardiovascular health: Semaglutide (SELECT trial) showed a 20% reduction in major adverse cardiovascular events in overweight/obese adults without diabetes. Tirzepatide cardiovascular outcome data is still being collected but early signals are positive.

Blood sugar control: All three were originally developed for type 2 diabetes and significantly improve glycemic control. Tirzepatide may have a slight edge here due to the dual mechanism.

Blood pressure: Weight loss from all three typically improves blood pressure.

Liver health: Both semaglutide and tirzepatide have shown benefit in non-alcoholic fatty liver disease (NAFLD/MASLD), with tirzepatide showing particularly strong results in the SYNERGY-NASH trial.

Sleep apnea: The SURMOUNT-OSA trials demonstrated that tirzepatide significantly improved obstructive sleep apnea severity, in some cases eliminating the need for CPAP.

Cost Comparison (2026)

| | Brand Price (Monthly) | Insurance Coverage | Compounded Available |

|---|---|---|---|

| Semaglutide | ~$1,000-1,350 | Improving | Yes |

| Tirzepatide | ~$1,000-1,100 | Improving | Yes |

| Liraglutide | ~$1,300-1,400 | Limited | Less common |

All three carry significant out-of-pocket costs without insurance. The availability of compounded versions — particularly for semaglutide and tirzepatide — has dramatically improved affordability for many patients. At CORAL, Dr. Kim helps patients navigate these options to find the most cost-effective approach that does not compromise quality or safety.

Insurance coverage has been expanding, particularly after the SELECT trial cardiovascular data strengthened the medical necessity argument for semaglutide. But coverage still varies significantly by plan, and prior authorization requirements remain common.

Which One Should You Choose?

There is no universal "best" GLP-1 medication. The right choice depends on several factors:

Consider tirzepatide if:

• You want maximum weight loss potential
• You have type 2 diabetes or significant insulin resistance
• You have NAFLD or sleep apnea
• You tolerate GI side effects reasonably well
• Cost/access is not a barrier

Consider semaglutide if:

• You want a well-established medication with extensive safety data
• Cardiovascular protection is a priority (SELECT trial data)
• You prefer the option of oral administration
• Compounded formulations make cost more manageable
• You want the broadest range of dosing flexibility

Consider liraglutide if:

• You have had significant GI intolerance with stronger GLP-1 agonists
• You prefer to start with a less potent option
• You are already on liraglutide for diabetes and want weight management benefits
• Your physician recommends it based on your specific medical profile

What About Combining GLP-1 Medications?

This is not recommended. You should not combine two GLP-1 receptor agonists — the side effect risk increases without proportional benefit. If one medication is not producing adequate results, your physician may consider switching to a different one rather than adding a second.

The Real-World Decision

Clinical trials provide averages, but you are not an average. Your metabolism, genetics, lifestyle, medical history, and personal preferences all factor into which medication will work best for you. Some patients respond dramatically to semaglutide and see little additional benefit from switching to tirzepatide. Others plateau on semaglutide and see renewed progress after switching.

The key is working with a physician who understands these medications well enough to guide the decision, monitor your response, and make adjustments as needed — not just write a prescription and check in months later.

---

CORAL offers physician-led telehealth consultations for GLP-1 weight loss management. Dr. Kim works with each patient individually to determine which medication, dose, and approach makes the most sense. [Start your consultation at coral.clinic/start](https://coral.clinic/start).